A fast screening method for the detection of CERA in dried blood spots.
Sign Up to like & getrecommendations! Published in 2021 at "Drug testing and analysis"
DOI: 10.1002/dta.3142
Abstract: Continuous erythropoietin receptor activator (CERA) is a third-generation erythropoiesis-stimulating agent that was developed for the treatment of anemia. However, misuse of CERA for doping in endurance sports has been reported. Previous studies have shown blood… read more here.
Keywords: blood spots; cera; detection cera; dried blood ... See more keywords
Early responsiveness to continuous erythropoietin receptor activator predicts renal prognosis and is determined by a novel antioxidative marker in non-dialysis chronic kidney disease: a prospective, observational, single-center study
Sign Up to like & getrecommendations! Published in 2020 at "Clinical and Experimental Nephrology"
DOI: 10.1007/s10157-020-01873-0
Abstract: Background Responsiveness to erythropoietin-stimulating agents (ESAs) is important for anemia management in chronic kidney disease (CKD). We assessed the effects of a continuous erythropoietin receptor activator (CERA) on renoprotection beyond anemia management and the correlation… read more here.
Keywords: responsiveness cera; continuous erythropoietin; chronic kidney; cera ... See more keywords
Potential effective treatment of shortening continuous erythropoietin receptor activator treatment interval combined with iron supplementation in hemodialysis patients.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of pharmacological sciences"
DOI: 10.1016/j.jphs.2021.05.010
Abstract: Our previous randomized controlled trial comparing the total dose of weekly versus biweekly continuous erythropoietin receptor activator (CERA) therapy to maintain optimal hemoglobin (Hb) levels showed no significant differences between the two therapies. This post-hoc… read more here.
Keywords: treatment; cera; iron supplementation; therapy ... See more keywords
Administration route governs the complication: A case report of anaphylaxis due to intravenous erythropoiesis‐stimulating agent
Sign Up to like & getrecommendations! Published in 2021 at "Nephrology"
DOI: 10.1111/nep.13846
Abstract: A 79-year-old man was admitted because of dyspnoea. He had been diagnosed with stage 5 chronic kidney disease and had been receiving monthly continuous erythropoietin receptor activator (CERA) subcutaneously. The chest radiograph showed cardiomegaly and… read more here.
Keywords: anaphylaxis due; session; cera; complication ... See more keywords
The Associations between Erythropoietic Response with Inflammation Markers and Perfluorinated Chemicals in Hemodialysis Patients
Sign Up to like & getrecommendations! Published in 2023 at "Healthcare"
DOI: 10.3390/healthcare11030442
Abstract: Erythropoiesis-stimulating agents (ESA) are used to treat anemia in hemodialysis (HD) patients. We investigated the role of inflammation and accumulation of environmental toxins (perfluorinated chemicals (PFCs), such as perfluorooctanoic acid and perfluorooctane sulfonate) in the… read more here.
Keywords: inflammation; perfluorinated chemicals; erythropoietic response; hemodialysis patients ... See more keywords